Avacta's Rapid Antigen Test Is Confirmed to Detect SARS-CoV-2 New Variants

Author's Avatar
Mar 08, 2021
Article's Main Image

Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION platforms, announces that the AffiDX® SARS-CoV-2 rapid antigen lateral flow test detects the dominant new variants of the coronavirus, known as the B117, or ‘Kent’, variant, and the D614G variant, as well as the original strain.